NCT00408967View on ClinicalTrials.gov

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Ovarian Cancer
Interventions
DRUG

Tucotuzumab celmoleukin (EMD 273066)

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT00408967 - Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | Biotech Hunter | Biotech Hunter